General Pharmacology

  • David R. Bickers


Adverse drug effects: The unintended consequences associated with normal doses of administered drugs.

Area under the curve: The plot of plasma concentration of drug against time after drug administration.

Bioavailability: The amount of unchanged drug reaching the bloodstream following administration by any route.

Clinical pharmacology: The scientific discipline dedicated to the study of drugs in humans.

Cytochrome P-450: Enzyme superfamily functioning as terminal components of the microsomal mixed function mono-oxygenase system that catalyzes the biotransformation of predominantly lipophilic molecules such as drugs and xenobiotics (chemical compounds that are foreign to a living organism) into inactive, more water-soluble species that can be more readily excreted from the body.


Stratum Corneum Percutaneous Absorption TPMT Activity Terminal Component Tazarotenic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ahmad N, Mukhtar H (2004) Cytochrome P450: a target for drug development for skin diseases. J Invest Dermatol 123:417–425PubMedCrossRefGoogle Scholar
  2. 2.
    Baron JM, Hoeller D, Schiffer R et al (2001) Expression of multiple cytochrome P450 enzymes and multidrug resistance-associated transport proteins in human skin keratino-cytes. J Invest Dermatol 116:541–548PubMedCrossRefGoogle Scholar
  3. 3.
    Baron JM, Wiederholt T, Heise R, Merk HF, Bickers DR (2008) Expression and function of Cytochrome p450-depen-dent enzymes in human skin cells. Curr Med Chem 15:2258–2264PubMedCrossRefGoogle Scholar
  4. 4.
    Fang J-Y, Leu Y-L (2006) Prodrug strategy for enhancing drug delivery via skin. Curr Drug Discov Technol 3:211–224PubMedCrossRefGoogle Scholar
  5. 5.
    Fox LP, Merk HF, Bickers DR (2005) Dermatological pharmacology. In: Brunton L, Lazo J, Parker K (eds) Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New YorkGoogle Scholar
  6. 6.
    Fromm MF (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Advanced Drug Deliv Rev 54:1295–1310CrossRefGoogle Scholar
  7. 7.
    Herkenne C, Naik A, Kalia YN et al (2007) Ibuprofen transport into and through skin from topical formulations: in vitro–in vivo comparison. J Invest Dermatol 127:135–142PubMedCrossRefGoogle Scholar
  8. 8.
    Ingelman-Sundberg M (2004) Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg's Arch Pharmacol 369:89–104CrossRefGoogle Scholar
  9. 9.
    Ingelman-Sundberg M, Sim SC, Gomez A et al (2007) Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526PubMedCrossRefGoogle Scholar
  10. 10.
    Lademann J, Richter H, Jacobi U et al (2008) Human percutaneous absorption of a direct hair dye comparing in vitro and in vivo results: implications for safety assessment and animal testing. Food Chem Toxicol 46:2214–2223PubMedCrossRefGoogle Scholar
  11. 11.
    Ogu C, Maxa JL (2000) Drug interactions due to cytochrome P450. Baylor U Med Ctr Proc 13:421–423Google Scholar
  12. 12.
    Rautio J, Kumpulainen H, Heimbach T et al (2008) Prodrugs: design and clinical applications. Nat Revs Drug Discovery 7:255–270CrossRefGoogle Scholar
  13. 13.
    Roden DM, Altman RB Benowitz NL et al (2006) Pharmacogenomics: challenges and opportunities. Ann Intern Med 145:749–757PubMedGoogle Scholar
  14. 14.
    Sahasranaman S, Howard D, Roy S (2008) Clinical pharmacology and pharmacokinetics of thiopurines. Eur J Clin Pharmacol 64:743–757CrossRefGoogle Scholar
  15. 15.
    Schiffer R, Neis M, Hoeller D et al (2003) Active infux transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratino-cytes. J Invest Dermatol 120:285–291PubMedCrossRefGoogle Scholar
  16. 16.
    Suzuki H, Sugiyama Y (2002) Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ ABCC2): its impact on drug disposition. Advanced Drug Deliv Rev 54:1311–1331CrossRefGoogle Scholar
  17. 17.
    Tang-Liu DD-S, Matsumoto RS, Usansky JI (1999) Clinical pharmacokinetics and drug metabolism of tazarotene. Clin Pharmacokinetics 37:273–287CrossRefGoogle Scholar
  18. 18.
    Tirona RG, Kim RB (2002) Pharmacogenomics of organic anion-transporting polypeptides (OATB). Advanced Drug Deliv Rev 54:1343–1352CrossRefGoogle Scholar
  19. 19.
    Zhang L, Strong JM, Qiu W et al (2006) Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharmaceutics 3:62–69CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.New York Presbyterian HospitalNew YorkUSA

Personalised recommendations